Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.254 CHF
−126.14 M CHF
158.42 M CHF
365.52 M
About Standard BioTools Inc.
Sector
Industry
CEO
Michael Egholm
Website
Headquarters
South San Francisco
Founded
1999
ISIN
US34385P1084
FIGI
BBG00LVDCKJ2
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Standard BioTools Inc. stocks are traded under the ticker FLB.
We've gathered analysts' opinions on Standard BioTools Inc. future price: according to them, FLB price has a max estimate of 1.62 CHF and a min estimate of 1.25 CHF. Watch FLB chart and read a more detailed Standard BioTools Inc. stock forecast: see what analysts think of Standard BioTools Inc. and suggest that you do with its stocks.
FLB stock is 0.00% volatile and has beta coefficient of 1.48. Track Standard BioTools Inc. stock price on the chart and check out the list of the most volatile stocks — is Standard BioTools Inc. there?
Today Standard BioTools Inc. has the market capitalization of 396.22 M, it has increased by 8.79% over the last week.
Yes, you can track Standard BioTools Inc. financials in yearly and quarterly reports right on TradingView.
Standard BioTools Inc. is going to release the next earnings report on Nov 11, 2025. Keep track of upcoming events with our Earnings Calendar.
FLB earnings for the last quarter are −0.04 CHF per share, whereas the estimation was −0.05 CHF resulting in a 25.07% surprise. The estimated earnings for the next quarter are −0.03 CHF per share. See more details about Standard BioTools Inc. earnings.
Standard BioTools Inc. revenue for the last quarter amounts to 17.27 M CHF, despite the estimated figure of 31.60 M CHF. In the next quarter, revenue is expected to reach 14.47 M CHF.
FLB net income for the last quarter is −26.55 M CHF, while the quarter before that showed −23.05 M CHF of net income which accounts for −15.19% change. Track more Standard BioTools Inc. financial stats to get the full picture.
No, FLB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 4, 2025, the company has 818 employees. See our rating of the largest employees — is Standard BioTools Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Standard BioTools Inc. EBITDA is −74.62 M CHF, and current EBITDA margin is −67.59%. See more stats in Standard BioTools Inc. financial statements.
Like other stocks, FLB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Standard BioTools Inc. stock right from TradingView charts — choose your broker and connect to your account.